A significant legal chapter has concluded for former shareholders of animal health company Covetrus. The path is now clear for a $70 million settlement following the expiration of the objection period this past Friday. As the firm resolves legal matters stemming from its privatization, it is simultaneously forging ahead with a multi-billion dollar strategic combination.
Strategic Expansion Through Merger
Beyond the courtroom, Covetrus is aggressively pursuing growth. In mid-February, the company reached an agreement with Cencora to combine with its MWI Animal Health division. Valued at approximately $3.5 billion, this transaction aims to unite two major players in the veterinary health and distribution sector. In exchange, Cencora will receive $1.25 billion in cash and preferred stock, retaining a minority stake of about 34% in the newly formed entity. The strategic objective is to integrate Covetrus’s technological platform with MWI’s extensive distribution network.
The completion of the MWI transaction, however, faces regulatory scrutiny and is not anticipated before the end of September 2026. Consequently, the integration of this new division is set to be a central operational focus for the upcoming fiscal year.
Should investors sell immediately? Or is it worth buying Covetrus?
Financing the Future
To fund the acquisition and subsequent integration, Covetrus’s owners, Clayton, Dubilier & Rice (CD&R) and TPG Capital, are currently negotiating a substantial refinancing package. Plans include a credit facility exceeding $3 billion, with financing partner Blue Owl Capital involved.
Analysts at S&P Global Ratings have provided projections for the post-merger entity. They forecast an adjusted EBITDA margin of roughly 5% for the combined company in 2026. Furthermore, as synergy benefits materialize, free cash flow is expected to rise to as much as $100 million by 2027. S&P also anticipates that the leverage ratio, measured as debt to EBITDA, will initially sit between 7.0x and 7.5x in 2026.
Resolution for Former Investors
The $70 million cash settlement fund is designated for investors who held shares prior to the company’s 2022 takeover by private equity firms CD&R and TPG Capital. The class action lawsuit centered on allegations concerning the company’s valuation and inadequate disclosures during the delisting process. A court hearing scheduled for April 13, 2026, is expected to finalize the distribution of funds, marking a pivotal milestone in resolving matters from its period as a publicly traded company.
Ad
Covetrus Stock: Buy or Sell?! New Covetrus Analysis from March 21 delivers the answer:
The latest Covetrus figures speak for themselves: Urgent action needed for Covetrus investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 21.
Covetrus: Buy or sell? Read more here...
